Related Experiment Video
Updated: May 2, 2026
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Oral anticoagulants for Asian patients with atrial fibrillation
Ian Sabir1, Kaivan Khavandi1, Jack Brownrigg2
1Rayne Institute, St Thomas' Hospital, London SE1 7EH, UK.
Insights
Non-vitamin K antagonist oral anticoagulants (NOACs) offer a safer and more effective alternative to warfarin for stroke prevention in Asian patients with atrial fibrillation (AF). These newer agents demonstrate comparable efficacy to warfarin with a reduced risk of bleeding complications.
Area of Science:
- Cardiology
- Pharmacology
- Public Health
Background:
- Atrial fibrillation (AF) poses a high stroke risk, particularly in Asian populations.
- Warfarin, a traditional anticoagulant, has suboptimal use in Asia due to unpredictable efficacy and high hemorrhage risk.
- Antiplatelet therapy is ineffective and unsafe for stroke prevention in Asian patients with AF.
Purpose of the Study:
- To review the use and efficacy of non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation (AF).
- To highlight the advantages of NOACs over warfarin and antiplatelet therapy in this specific demographic.
Main Methods:
- Review of international, randomized, controlled trials comparing NOACs (dabigatran, apixaban, edoxaban, rivaroxaban) with warfarin.
- Analysis of data on stroke prevention, systemic embolism, and bleeding events, including intracranial hemorrhage and major hemorrhage.
Main Results:
- NOACs demonstrated noninferiority to warfarin in preventing stroke and systemic embolism.
- NOACs were associated with a significantly lower incidence of major hemorrhage and intracranial hemorrhage compared to warfarin.
- Antiplatelet therapy was found to be neither safe nor effective for stroke prevention in Asian individuals with AF.
Conclusions:
- NOACs represent a safe and effective alternative to warfarin for anticoagulation in Asian patients with AF.
- The favorable bleeding profile of NOACs, particularly reduced intracranial hemorrhage rates, makes them a preferred option for this high-risk population.
- Further research and clinical adoption of NOACs are crucial for improving stroke outcomes in Asian individuals with AF.
Abstract:
Anticoagulation is the most-important intervention to prevent stroke in patients with atrial fibrillation (AF). Despite a lower point prevalence of AF in Asian communities and Asian countries than in other populations, individuals of Asian ethnicity are at a disproportionately high risk of stroke and have greater consequent mortality. Warfarin and other vitamin K antagonists are conventionally used for anticoagulation, and demonstrably reduce the risk of stroke and all-cause mortality in patients with AF. The use of warfarin in Asian countries is suboptimal, primarily owing to the universal challenge of achieving controlled anticoagulation with an unpredictable drug as well as concerns about the particularly high-risk of haemorrhage in Asian patients. Instead, antiplatelet therapy has been favoured in Asian communities, this strategy is neither safe nor effective for stroke prevention in these individuals. The non-vitamin K antagonist, oral anticoagulant drugs offer a solution to this challenge. The direct thrombin inhibitor dabigatran, and the direct factor Xa inhibitors apixaban, edoxaban, and rivaroxaban, have demonstrated noninferiority to warfarin in the prevention of stroke and systemic embolism in international, randomized, controlled trials. Importantly, some of these drugs are also associated with a significantly lower incidence of major haemorrhage, and all result in lower rates of intracranial haemorrhage and haemorrhagic stroke than warfarin. In this article, we review the use of the non-vitamin K antagonist anticoagulants in the management of AF in Asian populations.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:29Venous Thrombosis III: Interprofessional Care
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers